|

Myeloproliferative Neoplasms (MPNs) Patient Registry

RECRUITINGSponsored by University Health Network, Toronto
Actively Recruiting
SponsorUniversity Health Network, Toronto
Started2015-04
Est. completion2027-10-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT02760238

Summary

The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

Diagnosis of one of the following myeloproliferative neoplasms (MPNs):

* Atypical CML (aCML)
* Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),
* Chronic myelomonocytic leukemia (CMML)
* Chronic neutrophilic leukemia (CNL),
* Essential thrombocythemia (ET),
* Juvenile myelomonocytic leukemia (JMML),
* Mastocytosis, MPN unclassifiable
* MPN/MDS unclassifiable,
* Primary myelofibrosis (PMF),
* Post-essential thrombocythemia myelofibrosis (post-ET MF),
* Post-polycythemia vera MF (post-PV MF)
* Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)

Exclusion Criteria:

* None

Conditions11

CancerChronic Eosinophilic Leukemia-not Otherwise SpecifiedEssential ThrombocythemiaLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeLeukemia, Myelomonocytic, ChronicLeukemia, Myelomonocytic, JuvenileMastocytosisMyelodysplastic-Myeloproliferative DiseasesNeoplasmsPolycythemia Vera

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.